









COVID-19 rapid guideline: managing the long-term effects of COVID-19

NICE guideline

Published: 18 December 2020

www.nice.org.uk/guidance/ng188

LONG COVID or Chronic COVID

- Identifying
- Assessing
- Managing

Acute COVID-19:

Signs and symptoms of COVID-19 for up to 4 weeks.

Ongoing symptomatic COVID-19:

Signs and symptoms of COVID-19 from 4 to 12 weeks.

Post COVID-19 syndrome:

Signs and symptoms developing during or after COVID-19 infection, continue for more than 12 weeks and are not explained by an alternative diagnosis.

Long COVID:

- Signs and symptoms that continue or develop after acute COVID-19
- Both ongoing symptomatic COVID-19 and post COVID-19 syndrome

Identifying people with ongoing covid-19 or post-covid-19 syndrome

- Recovery time is different for every one
- For many people will resolve by 12 weeks
- Is not thought to be linked to the severity of the acute covid-19 episode.
- And new or ongoing symptoms can change unpredictably and affect in different way and time

 Do not predict whether a person is likely to develop post covid-19 syndrome based on severity and hospitalization Common symptoms of ongoing symptomatic COVID-19 & post COVID-19 syndrome:

Respiratory symptoms:

- 1. Cough
- 2. Breathlessness

Cardiovascular symptoms:

- 1. Chest tightness
- 2. Chest pain
- 3. Palpitations

Generalised symptoms:

- 1. Fatigue
- 2. Fever
- 3. Pain

Neurological symptoms :

- 1. Cognitive impairment (loss of concentration or memory)
- 2. Headache
- 3. Sleep disturbance
- 4. Peripheral neuropathy (numbness, pain, needles)
- 5. Dizziness
- 6. Delirium

Gastrointestinal symptoms:

- 1. Abdominal pain
- 2. Nausea
- 3. Diarrhoa
- 4. Anorexia & reduce appetite

Musculoskeletal symptoms:

- 1. Joint pain
- 2. Muscle pain

Psychiatric symptoms:

- 1. Depression
- 2. Anxiety

Ear , nose and throat symptoms :

- 1. Tinnitus
- 2. Earache
- 3. Sore throat
- 4. Dizziness
- 5. Loss of taste and/or smell

Dermatological:

1. Skin rashes

Neuropsychiatric sequelae of COVID-

- Depression
- Bipolar disorder
- Post traumatic stress disorder
- Psychosis
- Obsessive compulsive disorder
- Epilepsy
- Alzheimer Disease
- Insomnia

Neuropsychiatric sequelae in COVID-19

- Anxiety
- Fatigue
- Agitation
- Impaired memory
- Delirium
- Altered consciousness

The most common psychiatric features in acute covid-19

- ■Insomnia 42%
- Anxiety 35.7%
- Impaired memory 34%
- Depressed mood 32.6%
- Confusion 28%

The most common psychiatric features in post covid-19 syndrome:

- Sleep disorders (subj) 100%
- ► Fatigue 19.3%
- Impaired memory 18.9%
- ► Irritability 12.8%
- Anxiety 12.3%
- ■Insomnia 12.1%
- Depression 10.5%

Pathophysiology:

- Systemic inflammation
- Cytokine release and flu like syndrome
- Long lasting hypoxia which affects the brain

Flu-like syndrome induced in animal models

- Anhedonia
- Anorexia
- **►**Fever
- Fatigue
- Sleep disturbances
- Confusion

Sleep disorders:

- Self reported sleep disturbance is up to 100%
- Assessment tools: subjective questionnaires, polysomnography, actigraphy
- ■By questionnaire: 67% within 1 mo, 64% within 3 mo, 57% within 6 mo,

Non- pharmacological management:

- Music at sleep
- Reduction of ambient noise
- Earplug
- Reduction of ambient light
- Scheduling of activities during day
- Day time mobilization

Pharmacological treatment:

Lorazepam 1-2 mg oral or parenteral PRN

If Contraindication for Benzodiazepin:

- -Amitriptyline 25 mg/daily
- ■Zolpidem 2.5 -5 mg PRN
- Quetiapine 5 mg /daily
- Olanzapine 5 mg/daily
- Trazodone 50 mg/ daily
- Melatonin 3-10 mg

For regulation of sleep/wake cycle:

Mirtazapine 7.5 mg

Depression in long COVID:

prevalence: 10.5%

Management for depression in long CVID

- ■Escitalopram 10 20 mg daily
- Serteralin 50_ 100 mg daily

Anxiety in long COVID:

Prevalence: 12.3%

Management for anxiety in long COVID

- For acute attacks: Lorazepam 1-2 mg PRN
- For long term treatment: Escitalopram 10- 20 mg daily

For acute psychosis/mania:

- Risperidone 4-8 mg daily
- Olanzapin 10-20 mg daily

Delirium in COVID-19:

Prevalence: up to 75% in ICU patients

TWO KEY POINTES

First:

Good general care:

1. Prevention: avoid deliriogenic medications such

Anticholinergics

2. Early detection

-Second:

Earlier use of pharmacological treatment

 The risk of harm to others may exceed risk of harm to individual in delirium type patient

Recommendations for reducing the risk of delirium:

- Regular orientation
- Treating pain
- Avoiding constipation
- Avoiding urinary retention
- Maintaining oxygenation

First line medications for delirium:

- Haloperidol: 1 to 20 mg in 24 hours
- Lorazepam; up to 2 mg in 24 hours
- Flumazenil

 Haloperidol is preferred because of respiratory depression If refractory: Olanzapine up to 30 mg in 24 hours

Psychiatric manifestations of Chloroquine:

- Disorientation
- Agitation
- Depression
- Suicidal ideas
- Hallucinations
- Irritability
- Rapid mood fluctuation
- Insomnia
- Personality change

